Company Insights

ABCL customer relationships

Explore interactive graphBrowse insights index
ABCL customer relationship map

AbCellera Biologics (ABCL): Partner‑led discovery revenue with long clinical tails and milestone optionality

AbCellera operates a high-throughput antibody discovery platform and monetizes primarily through multi-year collaboration agreements with pharma and biotech partners, generating near-term services and research revenue while retaining upside via milestones and downstream royalties when partnered molecules reach the market. The company’s commercial profile is a hybrid: repeatable research fees today, asymmetric clinical and royalty upside over a multi‑year horizon. For focused access to these relationship signals, visit https://nullexposure.com/.

The commercial model in plain English

AbCellera sells discovery expertise and technology access to large and small drug developers. Contracts are partner‑led and multi‑year in most cases, with scope ranging from single‑target discovery to up‑to‑double‑digit target decks; payment mechanics mix upfront fees, per‑project research payments, milestone triggers and potential royalties. This posture produces predictable service revenue but concentrates the company’s long‑term value on partners’ clinical success and on a smaller set of programmes that will ultimately carry royalties.

  • Contracting posture: largely partner‑sponsored projects where AbCellera executes discovery and early characterization.
  • Revenue composition: majority services/R&D testing today, increasing reliance on milestone/royalty streams if partnered molecules advance.
  • Maturity and criticality: many relationships are early‑stage or discovery‑stage, implying long clinical timelines and variable revenue realization.

For a deeper signal view of customer relationships, see https://nullexposure.com/.

Relationship roll call — who AbCellera works with (concise takeaways)

Below I cover every relationship listed in ABCL’s FY2025 disclosures and related reporting. Each entry is a plain‑English summary followed by the source.

  • Eli Lilly and Company (LLY): Partnered across infectious disease and multi‑target programs; AbCellera supported marketed EUA antibodies Bamlanivimab and Bebtelovimab and maintains multi‑year collaborations in immunology, cardiovascular and neuroscience (noted July 31, 2024). According to ABCL’s FY2025 Form 10‑K, Lilly is a strategic, revenue‑generating partner with both marketed and discovery‑stage programmes (FY2025 10‑K).

  • AbbVie Inc. (ABBV): A multi‑target, multi‑year oncology collaboration disclosed January 13, 2025, positioning AbbVie as a sizable partner in oncology discovery work. This relationship is documented in ABCL’s FY2025 Form 10‑K (FY2025 10‑K).

  • Autolus Therapeutics plc (AUTL): A single‑target collaboration focused on CAR‑T cell therapy (noted Nov 29, 2018); this is a discrete, programme‑level engagement in cell therapy discovery (FY2025 10‑K).

  • Biogen Inc. (BIIB): A single‑target neuroscience collaboration established March 11, 2024, reflecting AbCellera’s footprint in CNS discovery projects (FY2025 10‑K).

  • Denali Therapeutics Inc. (DNLI): Partnered on TAK‑920/DNL919 (Phase 1/2) in neurology under a partner‑led arrangement, indicating AbCellera’s role in discovery towards early clinical assets (FY2025 10‑K).

  • EQRx, Inc. (EQRX): Multi‑target, multi‑year collaboration initially focused on oncology and immunology (agreement noted Aug 4, 2021), consistent with AbCellera’s commercial model of portfolio discovery mandates (FY2025 10‑K).

  • Gilead Sciences, Inc. (GILD): An agreement covering eight targets on a multi‑year basis (April 1, 2021), underlining Gilead as a substantial repeat customer for scaled discovery work (FY2025 10‑K).

  • IGM Biosciences, Inc. (IGMS): Multi‑target collaboration in oncology and immunology (Sept 24, 2020), a mid‑sized biotech partner leveraging AbCellera’s technology (FY2025 10‑K).

  • Incyte Corporation (INCY): An undisclosed oncology collaboration noted Sept 13, 2023, representing additional pharma interest in AbCellera’s discovery capabilities (FY2025 10‑K).

  • Kodiak Sciences Inc. (KOD): Multi‑target, multi‑year ophthalmology collaboration (Oct 29, 2020), indicating sector diversity beyond oncology/infectious disease (FY2025 10‑K).

  • Moderna, Inc. (MRNA): Agreement for up to six targets focusing on RNA‑encoded antibodies (Sept 15, 2021), highlighting platform interplay between discovery and novel modalities (FY2025 10‑K).

  • Novartis AG (NVS): Up to ten targets on a multi‑year basis (Feb 14, 2019), placing Novartis among AbCellera’s large‑scale strategic partners (FY2025 10‑K).

  • Pfizer Inc. (PFE): Multi‑target, multi‑year collaboration focused on membrane proteins (Jan 5, 2017), a long‑standing partnership in discovery (FY2025 10‑K).

  • Regeneron Pharmaceuticals, Inc. (REGN): Up to four targets on a multi‑year basis (Sept 20, 2023), another large pharma collaboration that underscores AbCellera’s enterprise traction (FY2025 10‑K).

  • Teva Pharmaceutical Industries Ltd. (TEVA): A partner‑led neuroscience programme at Phase 1 (FY2025 10‑K), reflecting cross‑industry reach including generic/ specialty companies.

  • Bruker Corporation (BRKR): Resolved a patent dispute with AbCellera that provides a US$36 million upfront payment plus future royalties and included an associated patent license; the settlement was reported in a December 18, 2025 press release and in subsequent coverage (PharmiWeb Dec 18, 2025; SimplyWall/TradingView March 2026).

  • Prelude Therapeutics (PRLD): Up to five targets, multi‑year oncology collaboration (Nov 1, 2023), a focused biotech engagement documented in the FY2025 10‑K.

  • Rallybio Corporation (RLYB): Up to five targets covering a rare metabolic disorder and undisclosed indications (Dec 1, 2022), reflecting tailored discovery mandates (FY2025 10‑K).

  • Everest Medicines Ltd.: Up to ten targets multi‑year in oncology and undisclosed areas (Sept 22, 2021), showing geographic and therapeutic breadth (FY2025 10‑K).

  • Abdera Therapeutics Inc. (ABDR): Multiple targets (nine) and a Phase 1 asset (ABD‑147) in oncology, indicating a deep discovery slate with Abdera (Jan 14, 2021; FY2025 10‑K).

  • GigaGen, Inc. (GIGA): GIGA‑564 Phase 1 oncology asset under a Trianni license—AbCellera’s technology licensing to specialty developers (FY2025 10‑K).

  • RQ Biotechnology Ltd. (RQBIO): Up to three infectious disease targets on a multi‑year basis (March 22, 2023), a focused infectious disease collaboration (FY2025 10‑K).

  • Dechra Pharmaceuticals (DPH): Animal‑health studies and pivotal work via partner‑led projects, illustrating AbCellera’s presence in veterinary biologics (FY2025 10‑K).

  • Arsenal Bio (ARSNL): AB‑2100 Phase 1/2 oncology programme under a Trianni license, adding to AbCellera’s oncology pipeline exposure (FY2025 10‑K).

  • NovaRock Biotherapeutics Inc. (NOVA): NBL‑012 Phase 1 (paused) across dermatology, GI and immunology via a Trianni license—a paused programme that nevertheless reflects prior deal flow (FY2025 10‑K).

  • Invetx, Inc. (INVTX): Multi‑target, multi‑year animal‑health collaboration (Nov 19, 2020) and joint pivotal work with Dechra, underscoring recurring animal‑health customers (FY2025 10‑K).

  • Tachyon Inc. (TACH): Single‑target oncology collaboration (Aug 3, 2021), another small‑cap partner using AbCellera’s discovery engine (FY2025 10‑K).

  • Empirico Inc. (EMP): Two additional undisclosed targets added May 3, 2022, showcasing incremental deal expansions with existing partners (FY2025 10‑K).

  • Angios (ANGIO): Multi‑target, multi‑year ophthalmology collaboration (May 6, 2021), reinforcing therapeutic diversification (FY2025 10‑K).

Constraints and investor implications

Company‑level signals in ABCL’s filings show two relevant constraints: (1) governmental reimbursement is cited as a commercial constraint, so downstream product economics will depend on payor coverage and public health policy; (2) services comprise the majority of current revenue, confirming the mixed model of contracted research income plus long‑dated upside. These constraints translate to clear investor implications: short‑term revenue stability from services, but earnings leverage and valuation upside are concentrated in the success of partner clinical programmes and in the conversion of royalties over time.

Final takeaways and what to watch next

AbCellera’s balance of predictable services revenue and high‑variance long‑term royalties makes it a play on discovery economics and partner execution. Key monitoring points are milestone receipts, royalty recognition from marketed partnered products, and the pace at which internal and partnered programmes advance through clinical stages. For more relationship intelligence and to track partner developments, visit https://nullexposure.com/.

If you want a relationship‑level dashboard or alerts for ABCL partner milestones, check https://nullexposure.com/ to subscribe to coverage and signals.